Mimedx Group Return on Equity (ROE) Growth & History (MDXG)
Mimedx Group's return on equity was 21.61% for fiscal 2025.
View full Mimedx Group company overviewMimedx Group annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 21.61% | −3.66 pp |
| 2024 | 2024-12-31 | 25.26% | −68.10 pp |
| 2023 | 2023-12-31 | 93.37% | — |
| 2020 | 2020-12-31 | −287.81% | −226.94 pp |
| 2019 | 2019-12-31 | −60.87% | −12.30 pp |
| 2018 | 2018-12-31 | −48.57% | −154.80 pp |
| 2017 | 2017-12-31 | 106.23% | +105.29 pp |
| 2016 | 2016-12-31 | 0.94% | −46.53 pp |
| 2015 | 2015-12-31 | 47.47% | +39.84 pp |
| 2014 | 2014-12-31 | 7.64% | +16.43 pp |
| 2013 | 2013-12-31 | −8.79% | +39.25 pp |
| 2012 | 2012-12-31 | −48.04% | +65.24 pp |
| 2011 | 2011-12-31 | −113.28% | — |
Mimedx Group quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −6.47% | −11.05 pp |
| Q1 2026 | 2026-03-31 | −4.35% | −7.90 pp |
| Q4 2025 | 2025-12-31 | 6.13% | +2.15 pp |
| Q3 2025 | 2025-09-30 | 7.35% | +2.71 pp |
| Q2 2025 | 2025-06-30 | 4.59% | −6.30 pp |
| Q1 2025 | 2025-03-31 | 3.55% | −2.66 pp |
| Q4 2024 | 2024-12-31 | 3.98% | −70.27 pp |
| Q3 2024 | 2024-09-30 | 4.64% | — |
| Q2 2024 | 2024-06-30 | 10.89% | — |
| Q1 2024 | 2024-03-31 | 6.21% | — |
| Q4 2023 | 2023-12-31 | 74.25% | — |
| Q4 2020 | 2020-12-31 | −260.69% | −240.48 pp |
| Q3 2020 | 2020-09-30 | −108.69% | −147.22 pp |
| Q2 2020 | 2020-06-30 | −31.83% | +22.78 pp |
| Q1 2020 | 2020-03-31 | −14.89% | +8.78 pp |
| Q4 2019 | 2019-12-31 | −20.21% | — |
| Q3 2019 | 2019-09-30 | 38.53% | — |
| Q2 2019 | 2019-06-30 | −54.60% | — |
| Q1 2019 | 2019-03-31 | −23.67% | — |
| Q4 2017 | 2017-12-31 | 3.95% | −2.44 pp |
| Q3 2017 | 2017-09-30 | 30.41% | +27.69 pp |
| Q2 2017 | 2017-06-30 | 7.53% | +5.85 pp |
| Q1 2017 | 2017-03-31 | 6.77% | +5.17 pp |
| Q4 2016 | 2016-12-31 | 6.40% | −13.39 pp |
| Q3 2016 | 2016-09-30 | 2.71% | −4.05 pp |
| Q2 2016 | 2016-06-30 | 1.67% | −4.37 pp |
| Q1 2016 | 2016-03-31 | 1.61% | −3.04 pp |
| Q4 2015 | 2015-12-31 | 19.78% | +15.29 pp |
| Q3 2015 | 2015-09-30 | 6.76% | +2.01 pp |
| Q2 2015 | 2015-06-30 | 6.05% | +6.56 pp |
| Q1 2015 | 2015-03-31 | 4.65% | +5.88 pp |
| Q4 2014 | 2014-12-31 | 4.49% | +7.11 pp |
| Q3 2014 | 2014-09-30 | 4.75% | +5.65 pp |
| Q2 2014 | 2014-06-30 | −0.52% | +1.83 pp |
| Q1 2014 | 2014-03-31 | −1.23% | +5.05 pp |
| Q4 2013 | 2013-12-31 | −2.62% | +5.58 pp |
| Q3 2013 | 2013-09-30 | −0.90% | +23.31 pp |
| Q2 2013 | 2013-06-30 | −2.35% | +2.94 pp |
| Q1 2013 | 2013-03-31 | −6.28% | +2.69 pp |
| Q4 2012 | 2012-12-31 | −8.19% | +13.51 pp |
| Q3 2012 | 2012-09-30 | −24.21% | −9.96 pp |
| Q2 2012 | 2012-06-30 | −5.28% | +21.03 pp |
| Q1 2012 | 2012-03-31 | −8.97% | — |
| Q4 2011 | 2011-12-31 | −21.70% | — |
| Q3 2011 | 2011-09-30 | −14.25% | — |
| Q2 2011 | 2011-06-30 | −26.32% | — |
Mimedx Group return on equity trends
Over the last five fiscal years, Mimedx Group's return on equity increased from −287.81% to 21.61%, a change of +309.41 percentage points. The latest reported quarter, Q2 2026, shows −6.47%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mimedx Group source filings ↗